AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Scienture Holdings, Inc.
Video analysis: SCNX
All videosNo video analysis for this stock yet. Request one from our team.
News: SCNX
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026
Management to Highlight Growing Commercial Momentum of Arbli ™ and the Commercial Launch of REZENOPY ™
SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company's Growing Commercial Revenue Base Q2 2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million Q2 2026 Net Loss Narrowed Approximately 58% Year-over-Year to Approximately $2.8 Million Commenced Commercial Launch of REZENOPY™, Establishing the Company's Second Commercial Product and Expanding Its Revenue-Generating Portfolio COMMACK, NY, Aug. 14, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the three and six months ended June 30, 2026.
SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray
Commercial launch supported by a dedicated national sales force, payer and institutional access, and multi-channel marketing campaign supporting adoption of REZENOPY ™
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
Commercial availability expected in August as the Company advances the rollout of the highest-dose FDA-approved naloxone hydrochloride nasal spray U. S. naloxone market totals ~$144 million in annual sales and ~9. 8 million units annually, represents significant commercial opportunity for REZENOPY COMMACK, NY, July 09, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC.
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
Commercial availability expected in August as the Company advances the rollout of the highest-dose FDA-approved naloxone hydrochloride nasal spray
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
Broader pharmacy access, channel expansion, and payer coverage position Arbli ™ for increased prescription volume and revenue growth
